Is Shionogi & Co., Ltd. (SGIOF) a Buy, Sell, or Hold?
OTC : SGIOF
Shionogi & Co., Ltd.
$17.55 USD
$0 (0.0%)
- Volume
- 500
- Average Volume
- 733
- Market Capitalization
- $14.93B
- P/E Ratio
- 11.93
- Dividend Yield
- 2.47%
- Price Target
- Year High
- $26.00
- Year Low
- $14.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.27
- Current Ratio
- $1.58
| Source | Headline |
|---|---|
|
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare. businesswire.com - 2026-05-13 17:08:00 |
